Precision Medicine Genomics Market

Oncology leads the precision medicine genomics market with 44.5% share, followed by hospitals and clinics at 40.8% by end user and next-generation sequencing at 39.1% by technology. Demand reflects stronger biomarker-guided treatment decisions, expanding clinical testing, and broad gene analysis, while reimbursement gaps and limited treatment access restrain adoption.